Cyprotex are proud to announce the launch of an enhanced and highly sensitive metabolite profiling and identification service using one of the most sensitive ion trap instruments in the industry.
The Applied Biosystems Sciex QTRAP® LC-MS/MS offers unparalleled sensitivity due to its novel Linear Accelerator™ trap. It allows accurate and precise ion detection over a wide dynamic range. The MS3 capability of the QTRAP® enables an improvement in selectivity and detection limits. Cyprotex have evaluated the QTRAP®5500 against its previous LC-MS/MS capabilities and found a profound enhancement in the ability to detect more minor metabolites.
The introduction of the QTRAP® 5500 LC-MS/MS is part of Cyprotex's expansion of our bioanalytical facility. As well as enabling us to enhance our metabolite profiling and identification service, it will also allow us to offer a comprehensive bioanalytical method development and validation service.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the improved service. "By investing in state of the art technology such as the QTRAP® 5500, we can offer our customers a first class bioanalytical service. Investigating the formation of drug metabolites at an early stage is recommended by the FDA and therefore metabolite identification is a critical part of the drug development process. Cyprotex is well placed to address this need."
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100